Astellas Pharma Inc. · Fiscal year ended March 2026
Five Astellas medicines added ¥143.9 billion in sales
Astellas develops and sells medicines for conditions including cancer and eye disease. Its major products, including XTANDI and PADCEV, are generally used by patients through prescriptions from healthcare professionals.

Five marketed medicines grew 43%
Different medicines serve different treatment needs
The five Strategic Brands have different sales scales
FY2025, year ended March 2026. Billions of yen, on one scale starting at 0. Individual product sales from the results presentation, p.6.
Source: FY2025 Financial Results, p.6
Providing medicines and investigating what comes next
Selling medicines and conducting research are different activities. Marketed medicines can also undergo development for additional indications.
XTANDI, five Strategic Brands and others
Prescribe for the indicated use
Use prescribed medicines in treatment
Research & development
External R&D partners
Combine internal researchers and external expertise
Availability and approved indications vary by country or region. This is not a distribution or payment map, and does not guarantee approval, commercial availability or treatment outcomes for investigational uses.
Sources: Medicines and Disease Areas / Research and Development / Results presentation, p.8
Group revenue reached ¥2.1392 trillion
XTANDI is still the largest medicine
One product accounts for about 45% of group revenue
FY2025. XTANDI share is a site calculation.
The 55.1% remainder already includes the Strategic Brands
XTANDI and the five brands account for 67.4% of revenue
Research spans 15 internal sites and external partners
Research combines disease biology and treatment technologies
The business operates in more than 70 countries and regions
Current product sales and the cost of research
Sales and R&D expense are FY2025 figures. The 70-plus-country footprint comes from the company overview, not a same-year revenue breakdown.
Plans for marketed medicines and future candidates
THE VIEW AFTER THE NUMBERS
What the numbers suggest
Astellas sells medicines while researching future medicines and additional uses. The five Strategic Brands’ ¥143.9 billion increase is an achieved result; future pipeline sales potential is an expectation.
Alongside XTANDI’s ¥960.8 billion, the company is building sales of medicines for different conditions and conducting research internally and with partners. Understanding its progress means keeping current revenue, R&D expense and future ambitions separate.
Primary sources used
FY2025 Financial Results
Astellas Pharma Inc. · 2026-04-27
Pages used: p.2,5-6,8 / p.5 / p.5-6
Open source →Medicines and Disease Areas
Astellas Pharma Inc.
Open source →About Astellas
Astellas Pharma Inc.
Open source →Research and Development
Astellas Pharma Inc.
Open source →Corporate Strategic Plan 2026
Astellas Pharma Inc.
Open source →